The blood-brain barrier is one of medicine's most stubborn gates. It keeps toxins out, but also blocks over 98% of potential therapeutics, particularly large-molecule biologic drugs like antibodies. For patients with brain tumors or central nervous system diseases, that gate has been a dead end. Nanocarry Therapeutics, a preclinical biotech spun out of Bar-Ilan University in 2021, is engineering a key. Its bet is a gold nanoparticle, smaller than a virus, designed to bind a therapeutic antibody on one side and, as the company puts it, "hitch a ride with insulin" on the other [Bar-Ilan University].
The core of the platform, called AxS, exploits a natural receptor-mediated transport system. Insulin receptors are abundant on the blood-brain barrier and act as a ferry service. By coating its nanoparticle to mimic insulin's binding properties, Nanocarry aims to trick the barrier into ushering a therapeutic payload directly into the brain. Preclinical studies cited by the university suggest the method can deliver up to 30 times more antibody to brain tissue than standard intravenous administration [Bar-Ilan University]. For lead candidate AxS-007, targeting brain metastases from HER2-positive breast cancer, that multiplier is the entire thesis.
A Plug-and-Play Bet on Platform Biology
Nanocarry's ambition extends beyond a single drug. The company describes its AxS system as a "Plug and Play" platform, engineered to be easily modified to carry a wide array of biologic drugs [LinkedIn]. This is the scalability argument. If the insulin-hitch mechanism works for one antibody, the logic runs, it could work for many. The initial pipeline focuses on high-need oncology: brain metastases from HER2+ breast cancer and non-small-cell lung cancer (NSCLC) [LinkedIn]. Success in either would validate the delivery mechanism and open the platform to partnerships for other CNS conditions, from neurodegenerative diseases to rare genetic disorders.
The strategic play is classic platform biotech. Prove the delivery vehicle in a high-value, tractable indication. Then license the technology to larger pharmaceutical companies sitting on libraries of biologic candidates that currently cannot reach the brain. Michal Roytman, listed as the company's Chief Business Officer, would be the point person for those conversations [Synapse-Patsnap]. The lack of disclosed partnerships or funding rounds, however, leaves the commercial strategy in the preclinical shadows.
The Long Road from Lab to Clinic
The science is elegant, but the path is perilously long and expensive. Nanocarry operates in the valley of death between academic research and clinical proof-of-concept. The company's public footprint is light on the operational details that de-risk such a journey.
- Capital intensity. Bringing a novel therapeutic through preclinical studies and into human trials requires tens of millions of dollars. No seed or Series A round has been publicly disclosed by major funding databases [Tracxn]. The company's runway and backing are unclear.
- Technical risk. The 30x delivery claim is from preclinical models. Translating that efficacy into humans, with all their biological complexity, is a formidable hurdle. The safety profile of repeatedly tricking the insulin transport system also remains unproven.
- Competitive landscape. While no direct competitors are named in the sources, the blood-brain barrier is a graveyard of failed approaches. Nanocarry's differentiation rests on the specificity of its insulin-receptor mechanism and its focus on biologics, but it is not the only team trying to pick this lock.
The company appears to be a lean operation, with public data suggesting a headcount between 2 and 20 employees [LinkedIn, Prospeo]. For now, the work is in the lab, advancing its lead candidates toward the inflection point of an Investigational New Drug (IND) application.
What Validates the Vehicle
For a platform bet at this stage, validation comes in non-dilutive grants and strategic interest. The next twelve months will be telling. Watch for a named pharmaceutical partner or a published research collaboration. A significant grant from an entity like the Israel Innovation Authority or the US National Institutes of Health would be a strong, non-equity signal of scientific merit. Most critically, the first disclosed funding round will put a number on investor conviction in the team and the technology. Who writes that first check? A specialist life sciences VC, a corporate venture arm from a big pharma with a CNS portfolio, or the university's own transfer office doubling down? The answer will define Nanocarry's immediate roadmap and credibility.
Sources
- [Bar-Ilan University] The Israeli Startup That's Breaching the Brain's Defenses | https://www.biu.ac.il/en/article/583781
- [LinkedIn] Nanocarry Therapeutics Company Page | https://il.linkedin.com/company/nanocarry-therapeutics
- [Synapse-Patsnap] Nanocarry Therapeutics Contact Information | https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/e23bc986063c0e3fa84c504579d6a7d6
- [Tracxn] NanoCarry Company Profile | https://tracxn.com/d/companies/nanocarry/__KzBHeN2ttmdgpEu_iYKIvMdQYDQHKGuJkuIUpsYCSwM
- [Prospeo] Nanocarry Therapeutics - Revenue, Employees, Funding | https://prospeo.io/c/nanocarry-therapeutics-revenue